- Lexaria’s DehydraTECH(TM) drug delivery platform a feasible and healthier alternative to other delivery methods
- The fast-acting, high absorption technology improves dipping experience and consumer satisfaction
- Company expects to more than double its 2019 revenue this year, will pursue a new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms and one of the few companies active in the field of cannabis to have developed formal relationships with Fortune 500 industry leaders, is experiencing strong demand from many companies requesting pre-processed DehydraTECH(TM)-enhanced bulk powders.
The company’s revolutionary drug delivery platform DehydraTECH(TM) accelerates human intestinal cell absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sugars or sweeteners, and other unhealthy practices. It is applicable to a wide variety of bioactive substances, including cannabis and nicotine. Utilization of the DehydraTECH(TM) drug delivery platform increases the absorption levels of CBD in human intestinal cells by 499%. As much as 1,937% more CBD is delivered into animal brain tissue after 8 hours using the enhanced technology in comparison with generic industry MCT coconut-oil formulations, according to recent studies.
Vaping and smoking have been shown to be dangerous methods of delivering drugs. Lexaria developed its technology as a safe and fast delivery method of bioactive substances via oral ingestion by bypassing potentially unhealthy practices such as inhalation. Proven to deliver up to 10 times more active ingredients in comparison to traditional edible, DehydraTECH(TM) is the first platform of its kind that allows users to access the primary benefits of inhalation – speed and efficiency – while circumventing the risks of inhalation.
The company currently has 16 patents granted and more than 60 patent applications worldwide. It is the only company to hold a patent for improved delivery of nicotine and all non-psychoactive and psychoactive cannabinoids, including tetrahydrocannabinol. The platform reduces the time of onset of THC by four times on average (http://cnw.fm/Aca2O).
Lexaria also obtained two patents for treating certain conditions including, but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia, and others. The platform has potential applications to assist treatment of the common form of dementia as well as other nervous system diseases.
In 2019, the company finalized a new contractual relationship with a GMP-certified, FDA registered production company to get enhanced DehydraTECH(TM) powders to market in the U.S. with current capacity of roughly 200,000 servings per day (http://cnw.fm/AwZr3).
The versatility and multiple potential applications of the DehydraTECH(TM) drug delivery platform, paired with the proven benefits it offers over other delivery methods, are some of the key factors driving demand and revenue growth for Lexaria Bioscience in 2020. The company expects to more than double its 2019 revenue this year from both existing clients and by leveraging a rich pipeline of prospective additional clients.
The company has already taken steps to increase the reach of its technology via a recent agreement with Cannadips Cannabis (http://cnw.fm/ZSf23). Under the definite agreement, Cannadips will use Lexaria’s technology to enhance its products available in California and nationwide. More specifically, DehydraTECH(TM) will be able to reduce throat irritation normally associated with some terpenes, which are part of the base ingredients of Cannadips THC. The 10-year licensing agreement is expected to considerably improve dipping experience and consumer satisfaction.
The expected revenue increase will support Lexaria’s future growth plans and its new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange. This move is anticipated to significantly increase the company’s market visibility and expand its customer base.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.